Search
N-(2-Aminoethyl)-1-aziridineethanamine
go.drugbank.com/drugs/DB15643ExperimentalFirst described in the literature in 2004, N-(2-Aminoethyl)-1-aziridineethanamine is an experimental angiotensin converting enzyme 2 inhibitor investigated for its use in treating cardiovascular disease
Categories: Agents Acting on the Renin-Angiotensin SystemSynonyms: N-(2-((2-Aminoethyl)amino)ethyl)aziridine, N-(2-aminoethyl)-1 aziridine-ethanamineFerric derisomaltose
go.drugbank.com/drugs/DB15617ApprovedInvestigational[A190528] Ferric derisomaltose is a form of iron used in the treatment of iron deficiency. This drug is a complex of iron (III) hydroxide and derisomaltose. … The latter is an iron carbohydrate oligosaccharide that works to release iron. Ferric derisomaltose was developed by Pharmacosmos Therapeutics ad was granted FDA approval in January 2020.
Products: Monofer 100 mg/ml solution for injection/infusion in vials, Monofer 100mg/ml solution for injection/infusion in ampoules2,2'-Dibenzothiazyl disulfide
go.drugbank.com/drugs/DB14201Approved2,2'-Dibenzothiazyl disulfide is an accelerator used in the processing process for natural and synthetic rubber and plastic regeneration. It is also a known allergen and dermatological sensitizer. … Sensitivity to 2,2'-Dibenzothiazyl disulfide may be identified with a clinical patch test.
Econazole
go.drugbank.com/drugs/DB01127ApprovedA broad spectrum antimycotic with some action against Gram positive bacteria. It is used topically in dermatomycoses also orally and parenterally.
Mixtures: TRILON-E CREAMAlanosine
go.drugbank.com/drugs/DB05540InvestigationalAn amino acid analogue and antibiotic derived from the bacterium Streptomyces alanosinicus with antimetabolite and potential antineoplastic activities.
Categories: Compounds used in a research, industrial, or household settingSynonyms: L-AlanosineIberdomide
go.drugbank.com/drugs/DB12101Investigationalat least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. … [L64055] Iberdomide has shown anti-tumor activity in multiple myeloma cells resistant to lenalidomide and pomalidomide, and as a CELMoD is designed to degrade Ikaros and Aiolos more potently than immunomodulatory
Categories: Cereblon E3 ligase modulatorVilanterol
go.drugbank.com/drugs/DB09082ApprovedInvestigational[A259961] Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds … [L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.
Vorasidenib
go.drugbank.com/drugs/DB17097ApprovedInvestigationalVorasidenib is a first-in-class dual isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor. … [A264209] Vorasidenib was first approved by the FDA on August 6, 2024, for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.[L51144]
Sevabertinib
go.drugbank.com/drugs/DB21667ApprovedInvestigational[L54638] It was granted accelerated approval by the FDA on November 19th, 2025.[L54608] … Sevabertinib is a kinase inhibitor indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain
Nylidrin
go.drugbank.com/drugs/DB06152ApprovedWithdrawnNylidrin is a peripheral vasodilator. … FDA has considered nylidrin as "lacking substantial evidence of effectiveness" in cerebral ischemia, cerebral arteriosclerosis, and other cerebral circulatory insufficiencies.